FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:2104-2107 November 17, 2005 Number 20 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Curtin, J. A. PubMed Citation

As with other cancers, the process of the transformation of normal melanocytes into malignant melanoma requires the acquisition of genomic abnormalities. Although progress in the search for the targets of genetic aberration in cancer has been stunning in many respects, the clinical effect of this work has been limited. But it is clear that tracking down the genetic changes in cancer is no mere academic exercise; rather, it has proved to be a powerful approach to the selection of therapeutic targets. Progress in the treatment of chronic myelogenous leukemia, gastrointestinal stromal tumor, and some lung cancers can be directly linked . . . [Full Text of this Article]

Source Information

Dr. Meltzer is head of the Section of Molecular Genetics, Cancer Genetics Branch, of the National Human Genome Research Institute, Bethesda, Md.

This article has been cited by other articles:

• Diaz-Cano, S. J., Ugurel, S., Houben, R., Becker, J. C., Vale, S., Miller, A., Mihm, M. C. Jr. (2006). Molecular mechanisms in melanoma.. NEJM 355: 1395-1396 [Full Text]  
• Goding, C., Meyskens, F. L. Jr. (2006). Microphthalmic-Associated Transcription Factor Integrates Melanocyte Biology and Melanoma Progression. Clin. Cancer Res. 12: 1069-1073 [Full Text]